LeaderMed, OPKO to Develop Treatments in Asia

LeaderMed, OPKO to Develop Treatments in Asia

306350

LeaderMed, OPKO to Develop Treatments in Asia

Two pharmaceutical companies, LeaderMed Health Group and OPKO Health, are teaming up to develop, manufacture, and commercialize two experimental medications in China and other locations in Asia. One of the investigational medicines, Factor VIIa-CTP, is being developed as a potential treatment for hemophilia. “Through this joint venture, we have an opportunity to extend the global availability of two of our novel long-acting development products and to establish a presence in China in partnership with collaborators…

You must be logged in to read/download the full post.